

Erforschung von Universum und Materie (ErUM) 2022-2025
BMBF-Project: Pharma-SAXS

**Pharma-SAXS: SAXS instrumentation for structure spectrum development of
lipid-based Nano-pharmaceuticals at DESY-PETRA-P12**

REFERENCES

- 1) [COVID-19 vaccine BNT162b1 elicits human antibody and T_H 1 T cell responses.](#)
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö., *Nature*. 2020 Oct 586, 594-599. doi: 10.1038/s41586-020-2814-7; <IF = 49.73>
- 2) [Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.](#)
 Kranz LM, Diken M, **Haas H**, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, **Langguth P**, Grabbe S, Huber C, Türeci Ö, Sahin U. *Nature*. 2016 Jun 16;534(7607):396-401 . doi: 10.1038/nature18300; <IF = 49.73>
- 3) [Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA.](#)
 Siewert CD, **Haas H**, Cornet V, Nogueira SS, **Nawroth T**, Uebbing L, Ziller A, Al-Gousous J, Radulescu A, Schroer MA, Blanchet CE, **Svergun DI**, Radsak MP, Sahin U, **Langguth P**; *Cells*. 2020 Sep 5;9(9):2034. doi: 10.3390/cells9092034; <IF = 4.33>
- 4) [Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.](#)
 Grabbe S, **Haas H**, Diken M, Kranz LM, **Langguth P**, Sahin U; *Nanomedicine (Lond)*. 2016 Oct;11(20):2723-2734. doi: 10.2217/nnm-2016-0275; <IF = 4.28>
- 5) [Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration.](#)
 Ziller A, Nogueira SS, Hühn E, Funari SS, Brezesinski G, Hartmann H, Sahin U, **Haas H**, **Langguth P**; *Mol Pharm*. 2018 Feb 5;15(2):642-651. doi: 10.1021/acs.molpharmaceut.7b01022; <IF = 4.32>
- 6) [Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.](#)
 Custódio TF, Das H, Sheward DJ, Hanke L, Pazicky S, Pieprzyk J, Sorgenfrei M, Schroer MA, Gruzinov AY, Jeffries CM, **Graewert MA**, **Svergun DI**, Dobrev N, Remans K, Seeger MA, McInerney GM, Murrell B, Hällberg BM, Löw C; *Nat Comm*.2020 Nov4;11(1):5588 doi: 10.1038/s41467-020-19204-y <IF = 13.78>
- 7) [Impact and progress in small and wide angle X-ray scattering \(SAXS and WAXS\).](#)
Graewert MA, **Svergun DI**; *Curr Opin Struct Biol*. 2013; 23:748-54 doi:10.1016/j.sbi.2013.06.007; **IF=7.87**
- 8) [Automated pipeline for purification, biophysical and X-ray analysis of biomacromolecular solutions.](#)
Graewert MA, Franke D, Jeffries CM, Blanchet CE, Ruskule D, Kuhle K, Flieger A, Schäfer B, Tartsch B, Meijers R, **Svergun DI**; *Sci Rep*. 2015 Jun 1;5:10734. doi: 10.1038/srep10734; <IF = 4.38>
- 9) [Adding Size Exclusion Chromatography \(SEC\) and Light Scattering \(LS\) Devices to Obtain High-Quality Small Angle X-Ray Scattering \(SAXS\) Data.](#)
Graewert MA, Da Vela S, Gräwert TW, Molodensky DS, Blanchet CE, **Svergun DI**, Jeffries CM; *Crystals* 2020 Oct;11, 975. doi: 10.3390/cryst10110975; <IF = 2.53>

- 10) [Versatile sample environments and automation for biological solution X-ray scattering experiments at the P12 beamline \(PETRA III, DESY\).](#)
Blanchet CE, Spilotros A, Schwemmer F, **Graewert MA**, Kikhney A, Jeffries CM, Franke D, Mark D, Zengerle R, Cipriani F, Fiedler S, Roessle M, **Svergun DI**; *J Appl Crystallogr.* 2015 Mar 12; 48(Pt 2):431-443. doi: 10.1107/S160057671500254X; <IF = 2.99>
- 11) [Preparing monodisperse macromolecular samples for successful biological small-angle X-ray and neutron-scattering experiments.](#)
Jeffries CM, **Graewert MA**, Blanchet CE, Langley DB, Whitten AE, Svergun DI; *Nature Protocols* 2016 Nov;11(11):2122-2153. doi: 10.1038/nprot.2016.113; <IF = 13.49>
- 12) [Enteric Hard Capsules for Targeting the Small Intestine: Positive Correlation between In Vitro Disintegration and Dissolution Times.](#)
Fu M, Al-Gousous J, **Blechar JA**, **Langguth P**; *Pharmaceutics.* 2020 Feb 3;12(2):123. doi: 10.3390/pharmaceutics12020123; <IF = 2.75>
- 13) [Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering.](#)
Uebbing L, **Ziller A**, Siewert C, Schroer MA, Blanchet CE, **Svergun DI**, Ramishetti S, Peer D, Sahin U, **Haas H**, **Langguth P**; *Langmuir* 2020; 36: 13331-13341. doi: 10.1021/acs.langmuir.0c02446; <IF = 3.77>
- 14) [Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems.](#)
Siewert C, **Haas H**, **Nawroth T**, **Ziller A**, Nogueira SS, Schroer MA, Blanchet CE, **Svergun DI**, Radulescu A, Bates F, Huesemann Y, Radsak MP, Sahin U, **Langguth P**; *Biomaterials.* 2019 Feb;192:612-620. doi: 10.1016/j.biomaterials.2018.10.020; <IF = 10.71>
- 15) [Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF\(mod\) estimated by combined time-resolved neutron and dynamic light scattering.](#)
Nawroth T, Buch P, Buch K, **Langguth P**, Schweins R; *Mol Pharm.* 2011 Dec 5;8(6): 2162-72. doi: 10.1021/mp100296w; <IF = 4.32>
- 16) [Fasted-State Simulated Intestinal Fluid “FaSSIF-C”, a Cholesterol Containing Intestinal Model Medium for *In Vitro* Drug Delivery Development.](#)
Khoshakhalagh P, Johnson R, **Langguth P**, **Nawroth T**, Schmueser L, Hellmann N, Decker H, Szekely NK; *J Pharm Sci* 104, 2213-2224; doi: 10.1002/jps.24470 <IF = 3.00>
- 17) [Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis.](#)
Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekić A, Knauer SK, Bantz C, **Nawroth T**, Bier C, Sirirattanapan J, Mann W, Treuel L, Zellner R, Maskos M, Schild H, Stauber RH; *ACS Nano.* 2011 Sep 27;5(9):7155-67. doi: 10.1021/nn201950e; ; <IF = 11.42>
- 18) [Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery.](#)
Nogueira SS, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, Blanchet CE, **Svergun DI**, Ramishetti S, Dan Peer D, **Langguth P**, Sahin U, **Haas H**; *ACS Appl. Nano Mater.* 2020, 3, 11, 10634–10645; doi: 10.1021/acsanm.0c01834; ; <IF = 4.86>
- 19) [Online coupling of field-flow fractionation with SAXS and DLS for polymer analysis.](#)
Thünemann AF, Knappe P, Bienert, Weidner S; *Anal Meth* 2009 3:177-182. doi: 10.1039/B9AY00107G
- 20) [Scalable Production of Lipid Nanoparticles Containing Amphotericin B.](#)
Kulkarni JA, Chen S, Tam YYC; *Langmuir* 2021 37:7312-7319. doi: 10.1021/acs.langmuir.1c00530